Merck, Inc.
🇵🇭Philippines
An Investigational Agent for the Treatment of Complicated Intra-Abdominal Infections or Acute Pelvic Infections (0826-038)
Phase 2
Completed
- Conditions
- First Posted Date
- 2004-09-24
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 100
- Registration Number
- NCT00092170
Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)
- First Posted Date
- 2004-09-14
- Last Posted Date
- 2017-06-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 859
- Registration Number
- NCT00091572
Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)
Phase 2
Completed
- Conditions
- First Posted Date
- 2004-09-14
- Last Posted Date
- 2017-04-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 74
- Registration Number
- NCT00091559
2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091)
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-08-27
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 922
- Registration Number
- NCT00090246
2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-090)(COMPLETED)
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-08-27
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 805
- Registration Number
- NCT00090155
Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED)
- First Posted Date
- 2004-08-27
- Last Posted Date
- 2017-04-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 477
- Registration Number
- NCT00090207
A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019)
- First Posted Date
- 2004-08-27
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 3819
- Registration Number
- NCT00090220
Rotavirus Efficacy and Safety Trial (REST)(V260-006)
- First Posted Date
- 2004-08-27
- Last Posted Date
- 2015-10-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 69274
- Registration Number
- NCT00090233
An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-08-27
- Last Posted Date
- 2018-08-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 4065
- Registration Number
- NCT00090285
A Single Dose of a Marketed Drug Being Studied for a New Indication to Treat Surgical Site Infection Following Colorectal Surgery as Compared to a Marketed Drug Approved for This Indication (0826-039)
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-08-27
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 952
- Registration Number
- NCT00090272
© Copyright 2024. All Rights Reserved by MedPath